Business
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as inducement
About this update from Avalo Therapeutics, Inc.
[{"type":"image","alt":"Avalo Therapeutics","displaySize":"","headline":null,"caption":"Avalo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ANi8XHp5jL2i.Q7JsBSgWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e","width":300,"height":161}},"lazy":false},{"type":"text","content":"WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).","length":620,"tagName":"p"},{"type":"text","content":"The Options were granted on November 4, November 10, and November 17, 2025, and entitle the recipients to purchase 24,000 shares of common stock, 72,000 shares of common stock, and 18,000 shares of common stock, respectively, at an exercise price per share equal to the closing price on the respective date on which the Option was granted. The Options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of each employee’s respective start date, and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Avalo through the applicable vesting dates. The Options are subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and the terms and conditions of an applicable stock option agreement covering the grant.","length":873,"tagName":"p"},{"type":"text","content":"About Avalo Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. O...